ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VRS Versarien Plc

0.108
0.00 (0.00%)
Last Updated: 08:00:09
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Versarien Plc LSE:VRS London Ordinary Share GB00B8YZTJ80 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.108 0.1005 0.1195 - 6,026,970 08:00:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chemicals & Chem Preps, Nec 5.45M -13.53M -0.0091 -0.12 1.61M
Versarien Plc is listed in the Chemicals & Chem Preps sector of the London Stock Exchange with ticker VRS. The last closing price for Versarien was 0.11p. Over the last year, Versarien shares have traded in a share price range of 0.058p to 1.90p.

Versarien currently has 1,488,169,507 shares in issue. The market capitalisation of Versarien is £1.61 million. Versarien has a price to earnings ratio (PE ratio) of -0.12.

Versarien Share Discussion Threads

Showing 52026 to 52049 of 204575 messages
Chat Pages: Latest  2087  2086  2085  2084  2083  2082  2081  2080  2079  2078  2077  2076  Older
DateSubjectAuthorDiscuss
24/8/2018
12:06
Can only sell 25k lumps AM, at 154.5pBut that's better than 9.30, when I fell back asleep!
festario
24/8/2018
12:05
It may be worth remembering that ground zero will shift when one or more new institutional investors appear on the VRS scene. It is entirely possible when/if some RNS's are published showing new institutional holders, apart from the share price shifting a gear up, a new baseline for the share price will be established. At that juncture, it would be perfectly reasonable to expect at least a doubling of the share price.

For this reason, and the newsflow, and the amazing potential of VRS, I will not be selling. I remain a relaxed and sanguine long term holder.

turbocharge
24/8/2018
12:05
I see Diplomat65 has had to send for backup ;-)
grabster
24/8/2018
12:04
What are the numbers looking like Fest?
andymoore07
24/8/2018
12:03
🍌 # ITS BANANA TIME! # 🍌
cdub1
24/8/2018
12:03
Why the pop at Fhasson?
festario
24/8/2018
12:00
Nice to see that Graham Stuart was also with Liam Fox.
rogerbridge
24/8/2018
11:59
ffahson one word idiot!!
ratpat999
24/8/2018
11:59
>>>Diplomat, I suggest you disregard anything Superg has to say about functionalisation, he clearly bears a grudge against Haydale (for some unknown reason) and he repeats himself ad nauseum about Haydale deceiving customers and investors regarding the need for functionalisation.

In fact Nanene is functionalised, it contains up to 2% oxygen and this is most certainly due to the oxygen containing functional groups at the terminal carbon atoms. This is why it can be dispersed in certain composites, if it did not have this functionalisartion, the dispersion properties would undoubtedly be poor

timbo003
24/8/2018
11:58
Ray to replace NR unfortunately CS.
sonsonnyjim
24/8/2018
11:57
Fhasson lol
chimpandy1
24/8/2018
11:56
Fyffes, is what's going on
pandar
24/8/2018
11:55
VRS is being taken over by Haydale
fhasson
24/8/2018
11:54
I think it’s VRS welcome to the world time :)
haz101
24/8/2018
11:53
I'm dreading a takeover approach. Don't care how astronomical a price someone pays now, will look a pittance in years to come. YouTube sold for $1.6bn in 2006? Looks like an absolute steal...
club sandwich
24/8/2018
11:51
I'm awake now. What's going on?
festario
24/8/2018
11:47
Lucky - was it you who said no poddy today (or any one) were did that info' come from?

Best wishes - spike

spike_1
24/8/2018
11:45
Looks like some of the AECOM team are coming to the investor golf day! I look forward to chatting with them along with hopefully meeting a few more on this board/twitter :)
a_game
24/8/2018
11:40
Fellow shareholders as Neill has said several times and live to us at the investor day don’t speculate about the properties of nanene / any of their business if you don’t know 100% ask Neill privately by email 1st !!
ratpat999
24/8/2018
11:39
And anyway - (Diplomat65 post 28913) - Haydale (and several others) offer a functionalising facility, to which Versarien have access if they want. (They have worked together before) So any story that NR is "desperate" to have such options is total nonsense. He already has them.
grabster
24/8/2018
11:38
160 today anyone?
pshevlin
24/8/2018
11:37
Liar they are homeless thanks to his shorting he's living in a tent
borg45
24/8/2018
11:31
Diplomat re functionalization. It's a bit semantic but some thoughts on the subject.

Somewhere in my research I came across Graphene made from very very pure Graphite. The graphite had no functional groups attached. When that graphite was used to make Graphene the resulting product was difficult to formulate in composites as it had no chemical groups attached. It could be made to work by adding functional groups but as sg says this can damage the resulting Graphene so care must be taken.
Now if you look at Nanene it's 98% carbon +/- 1%. There's a small quantity of oxygen, nitrogen, sulphur etc. We know Nanene can in many cases be blended into composites without further functionalization.
My assumption is that the very small non carbon element in Nanene is sufficient 'functionalization' to allow it to be dispersed.
As I say it's semantics but you could say Nanene is functionalised and doesn't need further action. 100% pure Graphene probably needs functionalising but that would be a very rare material. I agree with sg that using a blank statement that all Graphene needs functionalizing is inaccurate.

serratia
24/8/2018
11:20
Interesting story

"It could take 10 years before the new treatment comes to market"

"bought for £623 million"


News story Published 23 August 2018

Bristol pharmaceuticals startup bought for £623 million
University spin-out - supported by UK Research and Innovation funding - acquired to develop 'groundbreaking' treatment for diabetes.

Ziylo has been bought in a £623 million deal by Novo Nordisk, the biggest maker of diabetes drugs in the world.

Effective and safe management of diabetes
The company - which was spun out of the University of Bristol 4 years ago - has pioneered a synthetic molecule that binds glucose in the bloodstream more effectively in the treatment of diabetes. It comes out of 20 years of research at the university.

This module could eliminate the risk of hypoglycaemia, where blood sugar falls below normal levels. Hypoglycaemia is the main risk to those using insulin therapy and can be dangerous if not treated properly, leading to seizures or coma.

With the acquisition, Novo Nordisk hopes to use the module to develop a new kind of insulin so that people with diabetes can manage their condition more safely.

It could take 10 years before the new treatment comes to market, with the £623 million deal staged based on the potential success of the treatment.

Research supported by Innovate UK and EPSRC
Ziylo was founded by Professor Anthony Davis, PHD student Dr Harry Destecroix and businessman Tom Smart.

The team has received various research and innovation support over the years to help translate their academic thinking into commercial application.

They went through the Innovation and Commercialisation of University Research (ICURe) programme, which helps university researchers explore the commercial potential of their idea, and were awarded £500,000 by Innovate UK to set up Ziylo.

Professor Davis - a supervisor at the Engineering and Physical Sciences Research Council’s Centre for Doctoral Training in Chemical Synthesis - has also been supported long-term by the council with 3 awards for his research.

Dr Harry Destecroix, Chief Executive and co-founder of Ziylo, said:

Novo Nordisk is the ideal company to maximise the potential of the Ziylo glucose binding molecules in glucose responsive insulins and diabetes applications. It brings hope of a truly groundbreaking treatment to diabetes patients.

curtain twitcher
Chat Pages: Latest  2087  2086  2085  2084  2083  2082  2081  2080  2079  2078  2077  2076  Older

Your Recent History

Delayed Upgrade Clock